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Abstract
Background: Numerous studies have demonstrated that functional mitochondria are required for tumorigenesis,
suggesting that mitochondrial oxidative phosphorylation (OXPHOS) might be a potential target for cancer therapy.
In this study, we investigated the effects of BAY 87-2243, a small molecule that inhibits the first OXPHOS enzyme
(complex I), in melanoma in vitro and in vivo.
Results: BAY 87-2243 decreased mitochondrial oxygen consumption and induced partial depolarization of the
mitochondrial membrane potential. This was associated with increased reactive oxygen species (ROS) levels, lowering
of total cellular ATP levels, activation of AMP-activated protein kinase (AMPK), and reduced cell viability. The latter was
rescued by the antioxidant vitamin E and high extracellular glucose levels (25 mM), indicating the involvement of
ROS-induced cell death and a dependence on glycolysis for cell survival upon BAY 87-2243 treatment. BAY 87-2243
significantly reduced tumor growth in various BRAF mutant melanoma mouse xenografts and patient-derived
melanoma mouse models. Furthermore, we provide evidence that inhibition of mutated BRAF using the specific
small molecule inhibitor vemurafenib increased the OXPHOS dependency of BRAF mutant melanoma cells. As a
consequence, the combination of both inhibitors augmented the anti-tumor effect of BAY 87-2243 in a BRAF mutant
melanoma mouse xenograft model.
Conclusions: Taken together, our results suggest that complex I inhibition has potential clinical applications as a single
agent in melanoma and also might be efficacious in combination with BRAF inhibitors in the treatment of patients
with BRAF mutant melanoma.
Keywords: Anti-tumor efficacy, Mitochondrial complex I, Reactive oxygen species (ROS), Oxidative phosphorylation
(OXPHOS), Small molecule inhibitor, BRAF mutant melanoma, Cancer metabolism
Background
It has been well established that cancer cells are character-
ized by an altered metabolism compared to normal cells.
In fact, cancer cells reprogram their metabolism to meet
increased energetic and anabolic needs, including those
for ATP, reducing equivalents (e.g., NADPH), lipids, pro-
teins, and nucleotides. The metabolic adaptation of cancer
cells enables rapid cell proliferation and sustained cell sur-
vival even in extreme tumor microenvironments exhibit-
ing hypoxia and nutrient deprivation [1]. Historically,
mitochondrial metabolism and oxidative phosphorylation
(OXPHOS) were considered to be expendable for the
metabolic demands of rapidly dividing cells [2, 3]. This
classical observation, made by Otto Warburg in the 1920s,
states that cancer cells convert glucose into lactate even in
the presence of sufficiently high oxygen levels. It is now
appreciated that mitochondrial metabolism is also pivotal
for the generation of building blocks required for cancer
cell proliferation and that the “Warburg effect” (also
known as aerobic glycolysis) does not fully compensate for
defects in mitochondrial ATP production due to damaged
mitochondria as originally proposed. In fact, the majority
of cancer cells display functional mitochondria and are
able to generate ATP through mitochondrial metabolism
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fueled by fatty acids and amino acids, such as glutamine
[4–9]. Additionally, cancer cells also require mitochondrial
oxidative metabolism to maintain their redox balance.
Depending on the cellular context, mitochondria substan-
tially contribute to the generation of cellular reactive oxy-
gen species (ROS). Under physiological conditions, ROS
formation at complex I and III of the mitochondrial elec-
tron transport chain is a natural by-product of mitochon-
drial ATP generation [10, 11] and occurs due to the
incomplete reduction of molecular oxygen. Specifically
in cancer cells, ROS appear to play a causal signaling
role in tumor development and progression by inducing
DNA mutations, genetic instability, and also pro-
tumorigenic signaling [12]. When ROS production
exceeds the capacity of intracellular ROS-detoxifying
systems, cell-toxic oxidative stress is induced. This
explains why cancer cells have to tightly control the bal-
ance between ROS generation and scavenging in order
to remain within the pro-tumorigenic range of ROS
levels [13]. In this sense, cancer cells display an in-
creased ROS scavenging capacity that prevents ROS
levels from reaching cytotoxic levels incompatible with
growth [14, 15].
Given the important role of OXPHOS in mitochondrial
and cell metabolism, its targeting may be useful in cancer
therapy development. The first OXPHOS complex, com-
plex I, constitutes the entry point of electrons and is a
known site of ROS production [16]. Interestingly, evidence
was provided showing that complex I inhibition by the
anti-diabetic biguanide metformin inhibits tumorigenesis
in vitro and in vivo [17–21]. Similarly, the biguanide phen-
formin might exert its anti-tumor effects by inhibiting
complex I [22]. However, metformin and phenformin were
used at very high concentrations to exert their anti-tumor
efficacy, with phenformin also exerting an increased risk of
lactic acidosis [23, 24].
In this study, we investigated the effects of BAY 87-2243,
a potent and selective small molecule inhibitor of mito-
chondrial complex I, on mitochondrial function and anti-
tumor activity. BAY 87-2243 has been shown to inhibit
hypoxia-inducible factor (HIF) gene activation and dis-
played anti-tumor activity in an in vivo non-small cell lung
cancer xenograft model [25]. However, the signaling mech-
anism by which BAY 87-2243 induced anti-tumorigenic
effects is still unclear, and it has not been tested in other
cancer models. Using BRAF mutant melanoma as a model
system, we here report that BAY 87-2243-mediated com-
plex I inhibition induced melanoma cell death in vitro and
reduced melanoma tumor growth in various mouse
models in vivo. Our results suggest that this effect is medi-
ated through BAY 87-2243-induced stimulation of mito-
chondrial ROS production, leading to oxidative damage
and subsequent cell death. Interestingly, we observed that
BAY 87-2243 displayed increased anti-tumor efficacy
compared to single agent treatment when combined with
the small molecule mutant BRAF inhibitor vemurafenib in
nude mice bearing BRAF mutant melanoma xenografts.
Methods
Animal studies and cell cultures
Tumor xenograft experiments were carried out on
female immune-deficient mice in full accordance with
the Interdisciplinary Principles and Guidelines for the
Use of Animals in Research, Marketing and Education
issued by the New York Academy of Sciences’ Ad Hoc
Committee on Animal Research. Human melanoma SK-
MEL-28 and G-361 cells were subcutaneously inocu-
lated in athymic nu/nu mice (28–32 g, aged 7–8 weeks,
Janvier) and Balbc/nude (18–25 g, aged 5–6 weeks,
Janvier) mice, respectively. A-375 and LOX-IMVI mel-
anoma cells were inoculated in scid (scid/scid) mice
(20–25 g, aged 15–17 weeks, Charles River). The melan-
oma xenograft mouse model was established by
subcutaneous injection into the right flank with 0.1 mL
SK-MEL-28 cells (3 × 10E6) mixed 1:1 with Matrigel or
0.1 mL A-375 cells (1.5 × 10E6) or LOX-IMVI cells
(1.5 × 10E6) mixed 1:1 with Matrigel or 5 × 10E6 G-361
cells in 100 % Matrigel (Becton Dickinson). Mice were
randomized into control and treatment groups when
tumors reached a size of more than 50 mm2. Treatment
with vemurafenib (20 mg/kg/twice daily) or BAY 87-2243
(9 mg/kg/day) was administered by oral gavage in
Ethanol/Solutol/Water (10/40/50). Body weight was moni-
tored as a measure for treatment related, acute toxicity.
Tumor areas (measured by caliper) were calculated
according to the formula width × length. The human mel-
anoma cell lines A-375, G-361, SK-MEL-5, SK-MEL-28,
LOX-IMVI, SK-MEL-2, IPC-298, CHL-1, and Colo-792
were obtained from American Type Culture Collection
(ATCC), grown at 37 °C and 5 % CO2. All cell lines were
routinely grown in standard medium recommended by
ATCC and supplemented with 10 % (v/v) fetal calf serum
(FCS, Life technologies). When not stated differently, all
experiments were carried out in phenol-red-free and
pyruvate-free DMEM assay medium containing 5 mM
glucose (Sigma), 2 mM GlutaMAX (Gibco), 5 % dialyzed
FCS (Gibco).
Western blot analysis
Melanoma cell lines (A-375, G-361, SK-MEL-5, SK-MEL-
28) were grown to 80 % confluency and incubated with
BAY 87-2243 (10 nM) or BAY 87-2243 (10 nM) in com-
bination with either vitamin E (25 μM) or NAC (5 mM)
for 8 or 16 h, whereas control samples were treated with
an equal volume of DMSO. Cells were lysed in 100 μl RIPA
lysis buffer (Roche) supplemented with complete protease
inhibitor cocktail (Roche). Lysates were clarified by
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centrifugation (13,200 g, 15 min, 4 °C). The supernatant
was transferred to a new tube, and protein levels were
quantitated using the BCA method (Thermo Fischer).
Using SDS-PAGE (Nu-PAGE 4–12 % Bis-Tris protein gels)
and Western blotting, 30–50 μg total protein were ana-
lyzed with the following antibodies: anti-phospho-AMP-ac-
tivated protein kinase (AMPK) (Thr172) (Cell Signaling,
#2531), anti-AMPK (Cell Signaling, #2532), anti-phospho-
RAPTOR (Ser792) (Cell Signaling, #2083), anti-phospho-
p38 (Thr180/Tyr182) (Cell Signaling, #4511), anti-p38 (Cell
Signaling, #9212), anti-NRF2 (Novus biologicals, NB100-
80011), anti-phospho-ERK1/2 (Thr202/Tyr204) (Cell Sig-
naling, #4377), anti-ERK1/2 (Cell Signaling, #9102), anti-
cleaved PARP (Asp214) (Cell Signaling, #9541), and
anti-β-actin (Sigma), followed by secondary goat-anti-
mouse (IRDye800CW) or secondary goat-anti-rabbit
(IRDye680LT) antibodies. Antibody signals were de-
tected and quantitated using a LI-COR instrument.
Analysis of bioenergetics using the Seahorse XF96
extracellular flux analyzer
Extracellular flux analyses were performed using the
Seahorse XF96 Extracellular Flux Analyzer (Seahorse
Bioscience). To determine the effects of vemurafenib,
XF96 tissue culture plates were seeded at 20,000 cells/
well. When adherent cells were fully attached, cells were
treated with either DMSO or vemurafenib (1 μM) for
72 h. Basal mitochondrial function and mitochondrial
stress in response to BAY-872243 were measured by
oxygen consumption rate (OCR) using the XF Mito
Stress Test Kit (Seahorse Bioscience). The XF Mito
Stress Test Kit reveals key parameters of mitochondrial
function: basal respiration, ATP production, and re-
spiratory capacity. Briefly, cells were seeded at equal
densities (20,000–30,000 cells/well) into XF96 tissue
culture plates. Cell media was changed 24 h after cell
seeding into unbuffered Dulbecco’s modified Eagle’s
medium (DMEM) containing 8.3 g/l DMEM (Sigma),
2 mM GlutaMAX (Invitrogen), 5 mM glucose (Sigma),
63.3 mM NaCl (Sigma), and adjusted pH to 7.4 with
NaOH. The drug injection ports of the XF96 Assay
Cartridge were loaded with assay reagents to a final
concentration of 1 μM oligomycin, 0.5 μM FCCP, 1 μM
rotenone, and 1 μM antimycin A. OCR and extracellular
acidification rate (ECAR) were measured under basal
conditions and/or after injection of various concentra-
tion of BAY 87-2243 following the XF Mito Stress Kit.
All treatment conditions were analyzed with six repli-
cates. The OCR values were normalized to cell numbers
plated. To this end, the cells were stained using Cyquant
(Life technologies) and fluorescence was measured
using a microplate reader (Tecan) with excitation at
485 nm and emission detection at 530 nm.
High-resolution respirometry
The culture medium was collected and the BRAF mutant
melanoma cells were trypsinized, washed, and resus-
pended to approximately 2 × 10E6 cells per 2 ml in the
collected culture medium and used to measure cellular
oxygen consumption. Oxygen consumption was measured
at 37 °C using polarographic oxygen sensors in a two-
chamber Oxygraph (Oroboros Instruments, Innsbruck,
Austria) as previously described [26]. Briefly, cells were
first allowed to respire at basal level for 10 min and then
inhibited acutely by a stepwise addition of increasing con-
centrations (0–100 nM) of BAY 87-2243 until respiration
was maximally blocked. Basal (routine) respiration was set
at 100 % to which all other data points were related.
Cell viability, cell death, metabolic assays, and flow
cytometry
Melanoma cells were seeded in 96 well plates in triplicates
at a density of 3000–5000 cells/well and incubated in
culture medium. The next day, the culture medium was
exchanged to assay medium as described above and cells
were treated with various concentrations of BAY-872243 or
DMSO added to media using a dispenser (HP D300 digital
dispenser). After 72 h, cell viability was measured using
CellTiter-Fluor (CTF, Promega) according to the manufac-
turer’s protocol. Fluorescence was detected (excitation
380 nm, emission 505 nm) in a microplate reader (Tecan)
after 30 min of incubation at 37 °C. IC50 values were calcu-
lated from triplicate experiments using GraphPad prism
software, using curves from plots of fluorescence intensity
vs. BAY 87-2243 in each cell line. For the analysis of time-
dependent effects of BAY 87-2243, cell viability was
assessed by crystal violet assay. Briefly, cells were seeded in
48 well plates, treated with BAY 87-2243 (10 nM) or
DMSO as control and after incubation stained with crystal
violet solution (0.5 % crystal violet, 30 % ethanol, 3 % for-
maldehyde). Then, plates were rinsed with water and crys-
tal violet incorporated by the cells was re-solubilized in 1 %
SDS solution. Absorbance at 550 nm was measured using a
microplate spectrophotometer (Benchmark Plus, Biorad).
Results are expressed as percentage of cell viability relative
to untreated controls.
For measurements of cell death, 2 ml cells were seeded
in six well plates at 200,000 cells/well. When adherent
cells were fully attached, culture media was removed
and replaced with assay media containing BAY 87-2243
(10 nM), vitamin E (25 μM), or DMSO as a control. Cell
death was measured after 72 h using propidium iodine
and flow cytometry.
Extracellular lactate was measured in assay medium of
treated cells using Cobas 6000 c501 analyzer (Roche).
Results were normalized to cell number.
ATP measurements were conducted using CTG
(Promega) according to the manufacturer’s protocol.
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For MitoTracker stainings, cells were seeded into 384
well imaging plates (cell carrier, Perkin Elmer) at 1000
cells/well in 30 μL and incubated over night at 37 °C
and 5 % CO2. Then, cells were treated with vemurafe-
nib (1 μM) or DMSO as control for 72 h. Mitotracker
Green FM (Invitrogen) staining was carried out using
manufacturer’s recommended protocols. The DNA dye
Hoechst was added to the MitoTracker staining solution
(in DMEM culture medium) to achieve a final concentra-
tion of 1 μg/ml Hoechst and 100 nM MitoTracker Green
FM. Cells were then incubated for 30 min at 37 °C and
5 % CO2. Afterwards, staining solution was removed and
50 μl/well pre-warmed medium was added. The cells were
then imaged with the Opera® spinning disk automated
microscope (Perkin Elmer), imaging six wells per condi-
tion with sites/well using a 20× objective utilizing separate
405 nm and 488 nm laser excitation. Imaging data was
subsequently analyzed using the MetaXpress Software
(Version 5, Molecular Devices). Nuclei segmentation and
mitochondrial staining quantification was performed on
using built in detection routines. As measurement for
mitochondrial mass, total mitochondria staining intensity
per well was divided by the total count of nuclei per well.
Data are represented as the mean ± SD normalized to rela-
tive cell number.
ROS measurements
To measure intracellular ROS levels, 5 μM cell permeable
dichlorofluorescein diacetate (CM-H2DCFDA) (Invitrogen)
or 5 μM cell permeable MitoSOX (Life technologies) were
used as fluorescent dyes. The non-fluorescent redox-
reactive dye CM-H2DCFDA can get oxidized by intracellu-
lar ROS yielding the fluorescent probe CM-H2DCF, which
is proportional to cytosolic ROS. MitoSOX describes the
non-fluorescent dye hydroethidium which gets oxidized by
superoxide radicals yielding the fluorescent ethidium
product. An equal number of cells were seeded in six well
plates, treated with various concentrations of BAY 87-
2243 or BAY 87-2243 (10 nM) in combination with vita-
min E (25 μM) or NAC (5 mM) as indicated or 16 h. Cells
were incubated with phenol-red-free assay medium con-
taining either CM-H2DCFDA or MitoSOX dye in for
30 min at 37 °C. Cells were then washed with PBS, trypsi-
nized, resuspended in PBS, and immediately analyzed by
flow cytometry.
Biochemicals
BAY 87-2243 was developed by Bayer Pharma AG [25].
Vemurafenib was obtained from APAC Pharma (Charge
CLEV11988-2-2 APAC lot APWJ20130901PLX). N-Acetyl-
cysteine (NAC) and vitamin E (α-tocopherol) were obtained
from Sigma.
Statistics
GraphPad software was used for statistical analysis. Statis-
tical analyses for the comparison of more than two groups
were performed by one-way ANOVA, followed by a
Sidak’s multiple comparison test (pairwise comparisons).
A two-tailed t test was performed to compare between
two groups (two-group comparisons). P < 0.05 was consid-
ered to indicate a statistically significant difference.
Results
Inhibition of mitochondrial complex I with BAY 87-2243
in melanoma cells induces cell death in vitro and reduces
tumor growth in vivo
BAY 87-2243 has been shown to be a highly potent and
selective inhibitor of mitochondrial complex I [25]. We
demonstrate that BAY 87-2243-mediated complex I in-
hibition induced significant reduction of cell viability in
a dose-dependent manner in several BRAFV600E (G-361,
SK-MEL-5, SK-MEL-28, and A-375) and also BRAF wild
type (SK-MEL-2, IPC-298, CHL-1, and Colo-792) melan-
oma cell lines. BAY 87-2243 showed highly potent activ-
ity with an estimated IC50 in the one-digit nanomolar
range after 3 days of treatment (Fig. 1a). Using the same
treatment protocol, BAY 87-2243 induced 70–80 % of
cell death and reduced viability in a time-dependent
manner (Fig. 1b, c).
To address whether BAY 87-2243-mediated complex I
inhibition is efficient at reducing melanoma tumor growth
in vivo, we tested the inhibitor in four BRAF mutant
melanoma xenograft models using G-361, SK-MEL-
28, A-375, and LOX-IMVI cancer cells. Upon sub-
cutaneous melanoma cell injection, tumors were
allowed to grow to around 50 mm2 before the mice
were treated with vehicle or 9 mg/kg BAY 87-2243
(once a day) by oral gavage (p.o.). BAY 87-2243 induced a
significant reduction in tumor size in all BRAF mutant
melanoma xenografts, as well as a reduction in tumor
weight without affecting body weight of the mice (Fig. 1d
and Additional file 1: Figure S1A, B, C). Interestingly, BAY
87-2243 has stronger activity in the slow-growing melan-
oma xenografts (G-361 and SK-MEL-28). Also, BAY 87-
2243 displayed a strong reduction in tumor growth in two
patient-derived BRAF melanoma models (MEXF 276 and
MEXF 1732) (Fig. 1e).
Inhibition of mitochondrial complex I with BAY 87-2243
blocks OXPHOS and triggers glycolysis in melanoma cells
To investigate the mechanism by which BAY 87-2243-
mediated mitochondrial complex I inhibition induced cell
death and anti-tumor activity in melanoma cells, we first
determined the direct effect of the inhibitor on mitochon-
drial oxygen consumption. Addition of BAY 87-2243
induced a dose-dependent reduction of basal OCR in A-
375 and SK-MEL-28 cells (Fig. 2a). Using polarographic
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oxygen sensors a strong reduction in OCR was also
already observed in the low nanomolar range matching
the IC50 viability results (Fig. 1a and Additional file 2:
Figure S2A). This indicates selective inhibition of mito-
chondrial complex I and rationalizes the use of minimal
concentrations of BAY 87-2243 that maximally inhibit cell
growth (Fig. 1a) and mitochondrial respiration (Additional
file 2: Figure S2A) in all further experiments.
In the same cells, the ECAR of the cell culture media,
an indirect readout of glycolysis, increased (Fig. 2b)
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Fig. 1 Inhibition of mitochondrial complex I with BAY 87-2243 in melanoma cells induces cell death in vitro and reduces tumor growth in vivo.
a BRAF wild type and mutant melanoma cells were treated with various concentrations of BAY 87-2243. Cell viability was measured after 72 h. IC50 values
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which was also accompanied with a significant rise in
extracellular lactate of BAY 87-2243-treated cells
(Fig. 2c). This data indicates that BAY 87-2243 in-
duced a gradual switch from OXPHOS to glycolysis
demonstrated by the immediate drop in OCR and the
time-dependent increase in the glycolytic product lactate
(Additional file 2: Figure S2B). Detailed investigation of
mitochondrial function showed that, in addition to de-
creasing basal OCR, BAY 87-2243 also resulted in dimin-
ished maximal respiratory capacity of the mitochondria,
which was seen upon the addition of the mitochondrial
uncoupler FCCP (Fig. 2d and Additional file 2: Figure
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S2C). Furthermore, BAY 87-2243 treatment induced a
partial mitochondrial membrane depolarization in melan-
oma cells which can potentially lead to an energy crisis
due to the lack in ATP production (Fig. 2e).
Complex I inhibition using BAY 87-2243 reduces ATP
levels and induces an energy crisis in melanoma cells
To further address the mechanism behind the BAY 87-
2243-induced anti-tumorigenic phenotype, cellular ATP
levels were measured. This also allowed us to investigate
the role of the observed changes in mitochondrial respir-
ation and membrane polarization. We show that BAY
87-2243 caused a drastic, dose-dependent decrease of
total cellular ATP levels in melanoma cell lines, 8 h after
inhibitor treatment (Fig. 3a). In order to determine if
this drop in ATP had an effect on metabolic signaling,
we looked at the activity of AMPK upon BAY 87-2243
treatment, a critical energy sensor that is activated by
low ATP levels. It has been shown that AMPK is acti-
vated in the liver in response to therapeutic doses of
metformin and phenformin due to mitochondrial com-
plex I inhibition [27]. Here, we found that BAY 87-2243
significantly induced phosphorylation and activation of
AMPK in melanoma cells (Fig. 3b) which is consistent
with the drop in ATP levels (Fig. 3a). BAY 87-2243 also
activated RAPTOR, a well-defined downstream target of
AMPK (Fig. 3c). These results suggest that BAY 87-2243
induces an energy crisis in melanoma cell lines, which
causes AMPK and RAPTOR activation. Interestingly,
BAY 87-2243-mediated complex I inhibition also re-
duced the activation of extracellular-signal-regulated
kinase 1/2 (ERK1/2) (Fig. 3d). Keeping in mind that BAY
87-2243 appeared to stimulate glycolysis (Fig. 2 and
Additional file 2: Figure S2) potentially leading to the de-
pletion of extracellular glucose, we next cultured the mel-
anoma cells in a medium with high glucose (25 mM).
Under these conditions cell viability was rescued (Fig. 3e),
AMPK was not activated (Fig. 3f) and cellular ATP con-
tent was not reduced in BAY 87-2243-treated melanoma
cells (Fig. 3g). Taken together, these results suggest that
melanoma cells require glucose-driven glycolysis for ATP
production to survive in the presence of BAY 87-2243.
BAY 87-2243-mediated complex I inhibition increases
mitochondrial and cytosolic ROS levels resulting in
ROS-mediated cell death
Next, we focused on already known outcomes of complex
I inhibition and their potential role in causing the anti-
tumorigenic phenotype upon BAY 87-2243 treatment. It is
well established that mitochondrial complex I constitutes a
major source of ROS which can be toxic to the cell at high
levels. Studies have shown that the known complex I in-
hibitor rotenone significantly induces the production of
high levels of mitochondrial ROS, leading to oxidative
stress [28, 29]. Interestingly, here, we found that culturing
BAY 87-2243-treated melanoma cells in excess glucose
media (25 mM) did not only stabilize ATP levels (Fig. 3g)
but also significantly decreased ROS levels (Fig. 3h).
To further investigate the effect of BAY 87-2243 on ROS
levels, we used the redox-reactive dye CM-H2DCFDA and
the mitochondrial targeted dye MitoSOX which measure
the levels of cytosolic and mitochondrial ROS, respectively.
As expected, BAY 87-2243 generated high levels of mito-
chondrial ROS, in a dose-dependent manner, as well as
cytosolic ROS over time in melanoma cells (Fig. 4a, b and
Additional file 3: Figure S3A).
In order to evaluate the downstream effects of the
BAY 87-2243-induced increase in ROS levels, we looked
at the well-established ROS marker nuclear factor
(erythroid-derived 2)-like 2 (NRF2), which is a transcrip-
tion factor and master regulator of the antioxidant re-
sponse. NRF2 is known to be stabilized upon ROS in
order for the cell to balance potentially cell-damaging
oxidative stress [30–32]. BAY 87-2243 induced the
stabilization of NRF2 in melanoma cells (Fig. 4c), which
was abrogated in the presence of high glucose (Fig. 4d).
To establish whether increased levels of ROS are re-
quired for BAY 87-2243-mediated cell death, we treated
melanoma cells with BAY 87-2243 in the presence of the
antioxidants vitamin E and the reduced glutathione pre-
cursor N-acetyl cysteine (NAC). First, we show that the
vitamin E and NAC reversed ROS levels upon BAY 87-
2243 treatment in melanoma cells (Fig. 4e, f and
Additional file 3: Figure S3B). Furthermore, NRF2 levels
were reversed by the addition of vitamin E in inhibitor-
treated melanoma cells (Fig. 4g). In addition to decreas-
ing ROS stress, the antioxidant treatment abrogated
BAY 87-2243-induced cell death, suggesting that ROS
might play a causal role in this process (Fig. 4h and
Additional file 3: Figure S3C). Our findings also trans-
lated into cell death and redox-regulated protein expres-
sion [33, 34]. The expression of the cell death marker
cleaved Poly (ADP-ribose) polymerase (PARP) is induced
by BAY 87-2243 and rescued in the presence of the anti-
oxidant vitamin E and NAC (Fig. 4i and Additional file
3: Figure S3D) and also by the addition of excess glucose
(Fig. 4j). Furthermore, we looked at the mitogen-
activated protein kinase (MAPK) p38, which is a well
characterized ROS sensor, described to induce ROS-
mediated cell death [30, 35]. Indeed BAY 87-2243 treat-
ment induced the activation of p38 MAPK which was
reversed by vitamin E treatment in melanoma cells
(Fig. 4k). Interestingly, BAY 87-2243-induced AMPK
activation was also rescued by the antioxidant (Fig. 4l).
Taken together, our data suggest that melanoma cells
rely on glycolysis and the resulting ATP production, as
well as on redox balance to survive in the presence of
BAY 87-2243. We show that BAY 87-2243-mediated cell
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death is caused by ATP depletion and ROS stress, which
can both be alleviated by the addition of excess glucose.
Vemurafenib increases mitochondrial density and
respiration in BRAF mutant melanoma cells
Our data show that BAY 87-2243 has substantial effects as
a single agent against melanoma in vitro and in vivo, in-
cluding BRAF mutant melanoma. Having established that
BAY 87-2243 treatment leads to a metabolic switch away
from OXPHOS making melanoma cells dependent on gly-
colysis, we next wanted to test whether the efficacy of
BAY 87-2243 could be enhanced by a therapeutic agent,
based on its mechanism of action. Recent studies have
highlighted that mutant BRAF inhibition makes melan-
oma cells dependent on OXPHOS and mitochondrial
ATP production [36]. In fact, the selective mutant
BRAFV600E inhibitor vemurafenib actively reduced glucose
uptake in BRAF mutant melanoma cell lines [37]. In
BRAFV600E melanomas, this switch to OXPHOS is seen in
conjunction with the development of drug resistance
against selective inhibitors which commonly occurs and
represents a major limitation to clinical efficacy [38, 39].
Since the mitochondrial complex I inhibitor BAY 87-
2243 impairs OXPHOS and causes the cells to use glycoly-
sis, it impinges on the dependency on mitochondrial
metabolism, which is forced by BRAF inhibitors like
vemurafenib. This opposing metabolic dependency sug-
gests a rationale for combining vemurafenib with BAY 87-
2243 in order to exploit the mitochondrial pathway that
vemurafenib-treated melanoma cells need in order to sur-
vive. Combination treatment could potentially increase
energy stress by taking away the respective adaptive meta-
bolic upregulation leading to augmented melanoma cell
death compared to single agent treatment.
To validate the vemurafenib literature data with regard
to proliferation, OXPHOS, mitochondrial function, and
biogenesis, BRAF mutant melanoma cells were treated
with vemurafenib for 72 h. We show that vemurafenib im-
paired melanoma cell proliferation (Fig. 5a) and increased
mitochondrial density (Fig. 5b). The mitochondrial density
of BRAF wild type cells, MeWo, was not affected by
vemurafenib (Fig. 5b). Furthermore, vemurafenib led to a
significant increase in basal and ATP-coupled oxygen con-
sumption rate which was not observed in BRAF wild type
cells (Fig. 5c, d). Our data suggests that vemurafenib
induces OXPHOS in BRAF mutant melanoma cells, mak-
ing it a good combination drug for BAY 87-2243.
Inhibition of complex I using BAY 87-2243 in combination
with vemurafenib attenuated BRAF mutant melanoma
tumor growth in vivo
In order to test the in vivo efficacy of BAY 87-2243 and
vemurafenib as single agents and in combination, we used
the inhibitors in a BRAF mutant melanoma cell xenograft
model. Upon subcutaneous injection of SK-MEL-28 mel-
anoma cell, tumors were allowed to grow to around
50 mm2 before the mice were treated with either vehicle,
9 mg/kg BAY 87-2243, 20 mg/kg vemurafenib, or a com-
bination of both inhibitors by oral gavage. We show that
mice treated with the combination of BAY 87-2243 and
vemurafenib have enhanced reduction in melanoma tumor
growth compared to the reduction seen in mice treated
with each agent alone (Fig. 6a, b). Furthermore, combin-
ation treatment augmented the effect on reduction in
tumor weight compared to single agent treatment without
affecting body weight of the mice (Fig. 6c, d). Our data in-
dicate that BAY 87-2243-mediated complex I inhibition, in
addition to its function as a single agent, may have thera-
peutic benefits in combination treatment with the mutant
BRAF inhibitor vemurafenib in melanoma.
Discussion
Selective inhibition of mitochondrial complex I with BAY
87-2243 in melanoma cells induces cell death in vitro and
reduces tumor growth in vivo
In recent years, mitochondrial metabolism has emerged as
a target for cancer therapy due to the appreciation of mito-
chondria as a central metabolic organelle required for
tumorigenesis [12, 19, 40]. However, there is still a lack of
selective cancer therapies targeting OXPHOS and mito-
chondrial metabolism. In this study, we used the mito-
chondrial complex I small molecule inhibitor BAY 87-2243
and investigated its effects in melanoma cells. In addition
to causing proliferation impairment and cell death in a
(See figure on previous page.)
Fig. 3 Complex I inhibition using BAY 87-2243 reduces ATP levels and induces an energy crisis in melanoma cells. a Melanoma cells were treated with
different concentrations of BAY 87-2243 and ATP was measured after 8 h. Oligomycin (1 μM) served as positive control (n= 3). b, c Melanoma cells were
treated with BAY 87-2243 (10 nM). Cell lysates were collected from treated cells (16 h) and probed with antibodies recognizing phospho-AMPK (Thr172),
total AMPK, c phospho-RAPTOR (Ser792), d anti-phospho-ERK1/2 (Thr202/Tyr204), and anti-ERK1/2. Actin was used as a loading control. e Melanoma cells
were treated with various concentrations of BAY 87-2243. Cell viability was measured in high (25 mM) and low (5 mM) glucose medium after
72 h (n = 3). IC50 values were calculated using GraphPad Prism. f A-375 cells were treated with BAY 87-2243 (10 nM) under low- (5 mM) and
high (25 mM) glucose conditions. Cell lysates were collected from treated cells (16 h) and probed with antibodies recognizing phospho-AMPK
(Thr172) and total AMPK. Actin was used as a loading control. g Melanoma cells were treated with BAY 87-2243 (10 nM) under low- (5 mM) and
high (25 mM) glucose conditions and ATP was measured after 16 h (n = 3). h A-375 cells were treated with BAY 87-2243 (10 nM) under low- (5 mM) and
high (25 mM) glucose conditions. Cytosolic ROS levels were measured using the ROS-reactive dye CM-H2DCFDA after 16 h (n= 3). Data are represented
as the mean ± SD. *p< 0.05
Schöckel et al. Cancer & Metabolism  (2015) 3:11 Page 9 of 16
A B C D
GFE
H
MitoSOX
(16h treatment)
G-361 A-375 SK-MEL28
0
1
2
3
4
5
Control
BAY 87-2243 [10 nM]
BAY 87-2243 [10 nM] + VitE [25 µM]
Cytosolic ROS levels
(16h treatment)
C
yt
o
so
lic
 R
O
S
 L
ev
el
s
C
M
-H
2D
C
F
D
A
  M
F
I (
A
U
)
G-361 A-375 SK-MEL-28 
0
1
2
3
4
Control
BAY 87-2243 [10 nM] + VitE [25 µM]
BAY 87-2243 [10 nM]
%
 d
ea
d
 c
el
ls
 (
P
I p
o
si
ti
ve
)
%
 d
ea
d
 c
el
ls
 (
P
I p
o
si
ti
ve
)
%
 d
ea
d
 c
el
ls
 (
P
I p
o
si
ti
ve
)
%
 d
ea
d
 c
el
ls
 (
P
I p
o
si
ti
ve
)
I J K L
C
yt
o
so
lic
 R
O
S
 L
ev
el
s
0
1
2
3
4
8h 16h
M
it
o
ch
o
n
d
ri
al
 R
O
S
 L
ev
el
s
M
it
o
S
O
X
 M
F
I (
A
U
)
0
2
4
6
8
8h 16h
C
M
-H
2D
C
F
D
A
 M
F
I (
A
U
)
BAY 87-2243 [10nM]BAY 87-2243 [10nM]
M
it
o
ch
o
n
d
ri
al
 R
O
S
 L
ev
el
s
M
it
o
S
O
X
 M
F
I (
A
U
)
A-375 SK-MEL-5G-361 SK-MEL-28
(72h treatment) (72h treatment) (72h treatment) (72h treatment)
DMSO
BAY 872243 [10nM]
BAY 872243 [10nM] + VitE [25µM]
DMSO
BAY 872243 [10nM]
BAY 872243 [10nM] + VitE [25µM]
DMSO
BAY 872243 [10nM]
BAY 872243 [10nM] + VitE [25µM]
DMSO
BAY 872243 [10nM]
BAY 872243 [10nM] + VitE [25µM]
0
10
20
30
40
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
Fig. 4 (See legend on next page.)
Schöckel et al. Cancer & Metabolism  (2015) 3:11 Page 10 of 16
A B
C D
Vemurafenib
(72h treatment)
logconc (  M)
vi
ab
le
 c
el
ls
 (
%
 o
f 
ct
rl
)
-4 -2 0 2
0
50
100
150 A-375
SK-MEL-28
G-361
SK-MEL-5
G-361 1.4
SK-MEL-5 6.0
SK-MEL-28 0.5
A-375 8.4
IC50 [µM]
Fig. 5 Vemurafenib increases mitochondrial density and respiration in BRAF mutant melanoma cells. a BRAF mutant melanoma cells were treated
with various concentrations of vemurafenib. Cell proliferation was measured after 72 h. IC50 values were calculated using GraphPad prism (n = 4).
b MitoTracker Green fluorescence (left) and quantification (right) (average intensity per cell) of BRAF mutant and BRAF wild type melanoma cells
treated with vemurafenib (1 μM) for 72 h (n = 3). c OCR was measured using Seahorse analyzer in BRAF mutant and BRAF wild type melanoma
cells after treatment with vemurafenib (1 μM) for 72 h (n= 3). d ATP-coupled OCR (after injection of oligomycin (1 μM)) was analyzed using Seahorse in
BRAF mutant melanoma cells after treatment with vemurafenib (1 μM) for 72 h (n = 3). Data are represented as the mean ± SD. *p < 0.05
(See figure on previous page.)
Fig. 4 BAY 87-2243-mediated complex I inhibition increases mitochondrial and cytosolic ROS levels resulting in ROS-mediated cell death. a G-361 cells
were treated with BAY 87-2243 (10 nM). Mitochondrial ROS levels were measured using the MitoSOX dye after 8 and 16 h (n= 3). b G-361 cells were
treated with BAY 87-2243 (10 nM). Cytosolic ROS levels were measured using the ROS-reactive dye CM-H2DCFDA after 8 and 16 h (n= 3). c–d Melanoma
cells were treated with BAY 87-2243 (10 nM) under (c and d) low- (5 mM) and d high (25 mM) glucose conditions. Cell lysates were collected from
treated melanoma cell lines (8 h) and probed with antibodies recognizing NRF2. Actin was used as a loading control. e–f Melanoma cells were treated
for 16 h with BAY 87-2243 (10 nM) alone or in combination with the antioxidant vitamin E (25 μM). e Mitochondrial and f cytosolic ROS levels
were analyzed using flow cytometry (n = 3). g SK-MEL-28 cells were treated with BAY 87-2243 (10 nM) alone or in combination with vitamin E
(25 μM). Cell lysates collected from treated SK-MEL-28 cells (16 h) were probed with antibodies recognizing NRF2. Actin was used as a loading
control. h BRAF mutant melanoma cells were treated with BAY 87-2243 (10 nM) alone or in combination with vitamin E (25 μM). Cell death was
measured after 72 h using propidium iodine (n = 3). i–j Melanoma cells were treated with BAY 87-2243 (10 nM) alone or in combination with
vitamin E (25 μM) under (i and j) low- and j high glucose conditions. Cell lysates collected from treated A-375 and G-361 cells (16 h) were probed with
antibodies recognizing cleaved PARP. Actin was used as a loading control. k–l BRAF mutant melanoma cells were treated with BAY 87-2243 (10 nM)
alone or in combination with vitamin E (25 μM). Cell lysates collected from treated cells (8 and 16 h) were probed with antibodies recognizing
k phospho-p38 MAPK and total p38 MAPK and l phospho-AMPK (Thr172) and total AMPK. Actin was used as a loading control. Data are represented
as the mean ± SD. *p < 0.05
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variety of BRAF mutant and wild type melanoma cells,
BAY 87-2243 also revealed strong anti-tumor activity as a
single agent in vivo. Interestingly, BAY 87-2243 reduced
tumor growth most effectively in slowly proliferating tu-
mors (e.g., the SK-MEL-28 xenograft model) when com-
pared to rapidly proliferating tumors (e.g., the A-375
xenograft model) (Fig. 1d and Additional file 1: Figure S1).
This observation might be explained by the fact that fast
proliferating tumors are more glycolytic therefore consume
more glucose than slow-growing tumors [41–43]. Hence,
these latter tumors are more OXPHOS-dependent and
therefore more sensitive to BAY 87-2243-induced complex
I inhibition. Based on our in vivo data, it is tempting to
speculate that tumor growth rate might be used as a bio-
marker readout of sensitivity to complex I inhibition.
In line with our observation that glycolytic tumors
are more resistant to complex I inhibition in vivo we
suggest that BAY 87-2243 might be more effective in
conditions of limiting glucose availability (e.g., in the
center of a tumor). Indeed, BAY 87-2243 did not affect
melanoma cell viability when 25 mM of extracellular
glucose was present in the cell culture media, whereas
at 5 mM glucose, the inhibitor induced ATP depletion
and melanoma cell death (Fig. 3). This suggests that
Fig. 6 Inhibition of complex I using BAY 87-2243 in combination with vemurafenib attenuated melanoma tumor growth in vivo. a Nude mice were
xenotransplanted with 3 × 106 SK-MEL-28 (50 % matrigel) human melanoma cells (n = 10 per group). Mice were treated orally (p.o.) with vemurafenib
(20 mg/kg, twice a day) or for combination studies with vemurafenib (20 mg/kg, twice a day) and BAY 87-2243 (9 mg/kg, once a day). Tumor volume
was measured. b Relative tumor size (%) of individual SK-MEL-28 xenograft tumors (tumor area at study end × 100 / tumor area at study begin). Partial
regression, <70 % (tumor size at study end > 30 % smaller than original tumor size at study start); stable disease, 70–120 % (tumor size between 30 %
smaller and 20 % bigger of original size); progressive disease, >120 % (tumor size at study end > 20 % bigger than original size). c Tumor
weights of individual SK-MEL-28 xenograft tumors. d Body weights of mice (n = 10) bearing human SK-MEL-28 xenografts treated orally (p.o.)
once daily with vehicle (ethanol/solutol/water = 10:40:50), or with vemurafenib (20 mg/kg, twice a day), or for combination studies with vemurafenib
(20 mg/kg, twice a day) and BAY 87-2243 (9 mg/kg, once a day). Data are represented as the mean ± SD. *p < 0.05
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BAY 87-2243 targets OXPHOS in melanoma cells and
that the effects thereof depend on the amount of extra-
cellular glucose (Additional file 4: Figure S4).
Several retrospective studies suggested that metformin,
commonly used in patients with type II diabetes, inhibits
complex I and shows anti-tumor effects [17–21]. In con-
trast to metformin, BAY 87-2243 showed strong anti-
proliferative effects at low nanomolar concentrations and
anti-tumor effects at lower doses. Furthermore, the efficacy
of metformin may be further limited by the expression of
organic cation transporters (OCTs) required for uptake
and subsequent inhibition of OXPHOS [44].
BAY 87-2243 induces cell death via an oxidative stress
mechanism
Compared to normal cells, cancer cells are characterized
by an increased rate of ROS production. To prevent oxida-
tive stress induction, cancer cells upregulate ROS-
detoxifying systems [30, 45, 46], thereby, keeping the ROS
level within its pro-tumorigenic range [14, 47]. Here, we
observed that BAY 87-2243 reduced cellular ATP levels
(Fig. 3a) and increased cellular ROS levels (Fig. 4a, b). This
increase was associated with higher levels of NRF2 and
phosphorylated p38 MAPK. Interestingly, BAY 87-2243
partially prevented ROS stimulation in 25 mM glucose
medium and in the presence of antioxidants (vitamin E
and NAC) (Figs. 3h, 4e, f and Additional file 3: Figure
S3B). Also, under these conditions, BAY 87-2243-induced
cell death was prevented (Fig. 4h and Additional file 3:
Figure S3C). This suggests that BAY 87-2243 inhibits
complex I and thereby stimulates ROS generation and
induction of oxidative stress to induce cell death. Alter-
natively, a (parallel) mechanism might be active in
which complex I inhibition renders the cells completely
dependent on glycolysis for ATP generation. When
extracellular glucose levels are limited (i.e., 5 mM), this
glycolytic switch is unable to prevent ATP depletion
and the ensuing cell death. Hence, BAY 87-2243
inhibits tumorigenesis through multiple mechanisms
including the induction of cancer cell death in condi-
tions where glucose concentration is limited (leading to
ATP depletion) and via induction of oxidative stress
and a ROS-mediated cell death (Additional file 4:
Figure S4). Although it remains to be determined
how high extracellular glucose levels lower ROS
levels, a similar phenomenon has been observed in
cells with inherited and inhibitor-induced complex I
deficiency [48].
The combination of vemurafenib and BAY 87-2243 aug-
ments anti-tumor effects in BRAF mutant melanoma
Upon treatment with the mutant BRAFV600E inhibitor
vemurafenib, melanoma cells upregulate mitochondrial
oxygen consumption and decrease glycolysis [36]. This
suggests that these cells switch their cellular ATP produc-
tion from glycolysis towards mitochondrial metabolism,
making their survival more dependent on mitochondrial
function. In contrast, chronic inhibition of complex I was
demonstrated to induce a fully glycolytic phenotype in pri-
mary human skin fibroblasts [49]. Since the latter is very
similar to the effects induced by BAY 87-2243 in this
study, we treated melanoma cells with a combination of
vemurafenib and BAY 87-2243. Under these conditions,
we expected that the vemurafenib-induced stimulation of
mitochondrial metabolism is counterbalanced by the in-
hibition of mitochondrial function using BAY 87-2243.
Interestingly, when compared to their use as single agents,
the combination of BAY 87-2243 and vemurafenib in-
duced augmented tumor regression in nude mice bearing
BRAF mutant melanoma xenografts (Fig. 6). In agreement
with our approach, additive effects between biguanides
and BRAF inhibitor vemurafenib have been demonstrated
previously [50, 51].
One explanation for the augmented anti-tumor effect
might involve the activating effect of BAY 87-2243 on
AMPK. It has been demonstrated that mutated BRAFV600E
suppresses the activity of AMPK by promoting inhibitory
phosphorylation of its upstream kinase (LKB1) by ERK1/2
and that this AMPK inhibition is critical for melanoma
cell proliferation and anchorage-independent growth [52].
Interestingly, we show that BAY 87-2243 suppresses the
phosphorylation of ERK1/2 possibly allowing AMPK acti-
vation. Our results suggest that BAY 87-2243 induces an
energy crisis in BRAF mutant melanoma cell lines ac-
companied by the downregulation of the RAF-MEK-
ERK signaling cascade, thereby, potentially allowing
activation of AMPK and RAPTOR (Fig. 3a, b, c, d, and
Additional file 4: Figure S4).
Another possible explanation for the augmented anti-
tumor effect of vemurafenib and BAY 87-2243 might be
the heterogeneous nature of tumors with respect to
oxygen availability. Relative to normal tissue, tumors
display a much steeper oxygen gradient with its level
dropping close to zero in necrotic core areas. Adapta-
tion to these hypoxic conditions is for instance medi-
ated through the stabilization of the transcription factor
HIF-1, which controls the expression of many genes
involved in glycolysis [53]. In this context, it was dem-
onstrated that BAY 87-2243 treatment suppressed HIF-
1α protein levels and the expression of HIF-1 target
genes in a H460 xenograft model [25]. This means that
BAY 87-2243 might be more effective when combined
with other treatments that lower the availability of oxy-
gen and extracellular glucose in cancer cells. Interest-
ingly, vemurafenib has been shown to suppress glucose
uptake in melanoma cells [37] and also in tumors from
patients with BRAFV600E melanoma [54]. Therefore, it
can be hypothesized that a therapeutic advantage is
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achieved in BRAF mutant melanoma tumors by first
blocking OXPHOS and adaptation to hypoxia with BAY
87-2243, followed by subsequent downregulating of
glycolysis using vemurafenib.
Conclusions
Compared to standard chemotherapy, vemurafenib ex-
tends melanoma survival up to 6 months [55, 56]. In spite
of dramatic initial tumor shrinkage in patients with
BRAFV600E melanoma, long-term efficacy is thwarted due
to emergence of drug resistance and drastic tumor re-
growth [57]. Here, we confirm previous findings that
melanoma cells adapt to BRAF inhibitors by upregu-
lating OXPHOS therefore validating our approach to
effectively target this pathway with the selective mito-
chondrial complex I inhibitor BAY 87-2243. Our
study holds promise for the design of future combin-
ation therapies by broadening the understanding of
how to prevent the development of resistance to
oncogene-targeted therapies which may increase their
initial therapeutic efficacy. Based on our findings, we
suggest combining vemurafenib with complex I inhib-
itors in BRAF mutant melanoma in order to diminish
the ability of cancer cells to adapt to either agent.
Additional files
Additional file 1: Figure S1. BAY 87-2243 reduces tumor growth in
melanoma cells in vivo. (A) Scid mice bearing established A-375 (1.5x106 cells/
mouse in 50 % matrigel, n = 10 per group) and LOX-IMVI (1.5 × 106 cells/
mouse in 50 % matrigel, n = 10 per group) human xenograft tumors were
treated orally (p.o.), once daily with vehicle (Ethanol/Solutol/Water = 10:40:50)
or BAY 87-2243 (9 mg/kg). (B) Tumor weights of human melanoma
xenografts (A-375, G-361, SK-MEL-28, LOX-IMVI) treated orally (p.o.),
once daily with vehicle (Ethanol/Solutol/Water = 10:40:50) or BAY 87-2243
(9 mg/kg). (C) Body weights of mice bearing patient-derived (MEXF 276,
MEXF 1732) and human melanoma xenografts (G-361 and SK-MEL-28) treated
orally (p.o.), once daily with vehicle (Ethanol/Solutol/Water = 10:40:50) or BAY
87-2243 (9 mg/kg). Data are represented as the mean ± SD. *p< 0.05.
Additional file 2: Figure S2. Inhibition of mitochondrial complex I with
BAY 87-2243 inhibits OXPHOS and triggers glycolysis in melanoma cells. (A)
OCR was measured using polarographic oxygen sensors in a two-chamber
Oxygraph (Oroboros) in melanoma cells. BAY 87-2243 was injected in
different concentrations (n = 3). (B) SK-MEL-28 and G-361 cells were
treated with BAY 87-2243 (10 nM) and the time-dependent production
of extracellular lactate was measured (n = 4). (C) OCR was measured
using Seahorse analyzer in G-361 cells. BAY 87-2243 was injected (black
arrow) in different concentrations followed by consecutive injections of
oligomycin (1 μM), FCCP (0.5 μM) and antimycin A (1 μM)/rotenone
(1 μM) (n = 6). Data are represented as the mean ± SD. *p < 0.05.
Additional file 3: Figure S3. Complex I inhibition causes oxidative stress
and ROS-mediated cell death. (A) G-361 and SK-MEL-28 cells were treated
with increasing concentrations of BAY 87-2243. Mitochondrial ROS levels
were measured using the MitoSOX dye after 24 hours (n = 2). (B) A-375 cells
were treated with BAY 87-2243 (10 nM) and the antioxidant, NAC (5 mM).
Cytosolic ROS levels were measured using the redox-reactive dye
CM-H2DCFDA after 24 h (n = 3). (C) Melanoma cells were treated with
BAY 87-2243 (10 nM) and the antioxidant NAC (5 mM). Cell death
was measured after 72 h using propidium iodine (n = 3). (D) G-361
cells were treated with BAY 87-2243 (10 nM, 100 nM) and the antioxidant,
NAC (5 mM). Cell lysates were collected from treated G-361 cells (24 h) and
probed with antibodies recognizing cleaved PARP. Actin was used as a
loading control. Data are represented as the mean ± SD. *p < 0.05.
Additional file 4: Figure S4. Melanoma cells are sensitive to BAY
87-2243-mediated Complex I inhibition by undergoing an energy
crisis and ROS-mediated cell death. Under limiting glucose conditions (5 mM),
the mitochondrial complex I inhibitor BAY 87-2243 induces a metabolic switch
from OXPHOS to glycolysis in melanoma cells. Results of BAY 87-2243-
mediated complex I inhibition include a reduction in the total cellular
ATP pool and therefore AMPK activation, suppression of ERK1/2
phosphorylation, and the induction of oxidative stress. ROS stress is
marked by stabilization of NRF2, phosphorylation of p38 MAPK, and
AMPK as well as cell death signaling marked by cleaved PARP.
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